Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia

Blood

Volumn 118, Issue 8, 2011, Pages 2191-2199

  Park, Eugene ^a   Gang, Eun Ji ^a   Hsieh, Yao Te ^a   Schaefer, Paul ^a   Chae, Sanna ^a   Klemm, Lars ^b   Huantes, Sandra ^a   Loh, Mignon ^b   Conway, Edward M ^c   Kang, Eun Suk ^d   Koo, Hong Hoe ^d   Hofmann, Wolf Karsten ^e   Heisterkamp, Nora ^a   Pelus, Louis ^f   Keerthivasan, Ganesan ^g   Crispino, John ^g   Kahn, Michael ^a   Müschen, Markus ^b   Kim, Yong Mi ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EZN 3042; EZN 3088; OLIGONUCLEOTIDE; SHORT HAIRPIN RNA; SURVIVIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CELL RENEWAL; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; HUMAN; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

EID: 80052148548     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-351239     Document Type: Article

References (49)

1. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010;116(5):1165-1176.
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-1043. (Pubitemid 351389536)
3. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29(5):551-565.
4. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983 - 1995. Leukemia. 2000;14(12):2223-2233.
5. Pui CH, Cheng C, Leung W, et al. Extended follow- up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003; 349(7):640-649. (Pubitemid 36975996)
6. Deveraux QL, Reed JC. IAP family proteins- suppressors of apoptosis. Genes Dev. 1999; 13(3):239-252. (Pubitemid 29095796)
7. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3(1):46-54. (Pubitemid 37328886)
8. Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem. 2004;279(33): 34087-34090. (Pubitemid 39318028)
9. Sun C, Nettesheim D, Liu Z, Olejniczak ET. Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry. 2005; 44(1):11-17. (Pubitemid 40095702)
10. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003;22(11):2729-2740. (Pubitemid 36712369)
11. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene. 2004;23(1):39-48. (Pubitemid 38142238)
12. Okada H, Mak TW. Pathways of apoptotic and nonapoptotic death in tumour cells. Nat Rev Cancer. 2004;4(8):592-603. (Pubitemid 39025054)
13. Speliotes EK, Uren A, Vaux D, Horvitz HR. The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol Cell. 2000; 6(2):211-223.
14. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396(6711):580-584. (Pubitemid 28563719)
15. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 2002;3(6):401-410. (Pubitemid 34685698)
16. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell. 2003;14(8): 3325-3341. (Pubitemid 37013130)
17. Fukuda S, Singh P, Moh A, et al. Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood. 2009; 114(2):394-403.
18. Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD. Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia. 2010;24(11):1920-1926.
19. Guha M, Altieri DC. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle. 2009;8(17):2708-2710.
20. Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood. 2001;97(9):2784-2790.
21. Bhojwani D, Kang H, Moskowitz NP, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2006;108(2):711-717. (Pubitemid 44061374)
22. Klemm L, Duy C, Iacobucci I, et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009;16(3):232-245.
23. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
24. Xing Z, Conway EM, Kang C, Winoto A. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med. 2004;199(1):69-80. (Pubitemid 38076479)
25. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998; 92(10):3780-3792. (Pubitemid 28525205)
26. Fisker N,Westergaard M, Hansen HF, Hansen JB. Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy. Nucleosides Nucleotides Nucleic Acids. 2007; 26(10-12):1427-1430. (Pubitemid 350240751)
27. Stein CA, Hansen JB, Lai J, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 2010;38(1):e3.
28. Sapra P, Wang M, Bandaru R, Zhao H, Greenberger LM, Horak ID. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid anti-sense oligonucleotide. Nucleosides Nucleotides Nucleic Acids. 2010;29(2):97-112.
29. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40(4): 1117-1123. (Pubitemid 32108606)
30. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58(23): 5315-5320. (Pubitemid 28551107)
31. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia. 2004;6(1):29-40. (Pubitemid 38391947)
32. Srinivasula SM, Ashwell JD. IAPs: what's in a name? Mol Cell. 2008;30(2):123-135. (Pubitemid 351626688)
33. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 2010;430(2):199-205.
34. Huang Y, Park YC, Rich RL, Segal D, Myszka DG, Wu H. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell. 2001;104(5):781-790. (Pubitemid 32241027)
35. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004;114(8): 1117-1127. (Pubitemid 39578701)
36. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003;278(25): 23130-23140. (Pubitemid 36830379)
37. Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002;62(9):2462-2467. (Pubitemid 34462718)
38. Lens SM, Medema RH. The survivin/Aurora B complex: its role in coordinating tension and attachment. Cell Cycle. 2003;2(6):507-510.
39. Samuel T, Okada K, Hyer M,Welsh K, Zapata JM, Reed JC. cIAP1 Localizes to the nuclear compartment and modulates the cell cycle. Cancer Res. 2005;65(1):210-218. (Pubitemid 40070812)
40. Pohl C, Jentsch S. Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. Cell. 2008;132(5):832-845. (Pubitemid 351312799)
41. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. IAP regulation of metastasis. Cancer Cell. 2010;17(1):53-64.
42. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: patent review. Expert Opin Ther Pat. 2010;20(12):1723-1737.
43. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67(17):8014-8021. (Pubitemid 47395135)
44. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BK. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther. 2011;10(2):221-232.
45. Hansen JB, Fisker N, Westergaard M, et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther. 2008;7(9):2736-2745.
46. Zhang Y, Qu Z, Kim S, et al. Down-modulation of cancer targets using locked nucleic acid (LNA)- based antisense oligonucleotides without transfection. Gene Ther. 2011;18(4):326-333.
47. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12(4):492-503.
48. Fabarius A, Giehl M, Frank O, et al. Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. Br J Haematol. 2007; 138(3):369-373. (Pubitemid 47035400)
49. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991;51(8):2212-2222.